Savara (NASDAQ:SVRA) Rating Reiterated by JMP Securities

JMP Securities restated their market outperform rating on shares of Savara (NASDAQ:SVRA) in a report released on Thursday, Benzinga reports. JMP Securities currently has a $8.00 price target on the stock.

Separately, Piper Sandler lifted their target price on Savara from $7.00 to $16.00 and gave the company an overweight rating in a research report on Monday, March 4th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of Buy and an average target price of $8.20.

Savara Price Performance

Shares of SVRA opened at $4.81 on Thursday. Savara has a 1 year low of $1.76 and a 1 year high of $5.70. The company has a debt-to-equity ratio of 0.19, a current ratio of 15.66 and a quick ratio of 15.66. The company has a market capitalization of $664.50 million, a price-to-earnings ratio of -14.58 and a beta of 0.77. The business has a 50-day moving average of $4.97 and a 200-day moving average of $4.41.

Savara (NASDAQ:SVRA) last issued its earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. As a group, equities research analysts anticipate that Savara will post -0.38 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. lifted its position in shares of Savara by 30.9% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company’s stock valued at $30,008,000 after buying an additional 1,874,000 shares during the last quarter. Jennison Associates LLC lifted its position in shares of Savara by 44.6% during the 3rd quarter. Jennison Associates LLC now owns 3,866,762 shares of the company’s stock valued at $14,616,000 after buying an additional 1,192,730 shares during the last quarter. Vivo Capital LLC purchased a new position in shares of Savara during the 3rd quarter valued at $7,232,000. Polar Capital Holdings Plc purchased a new position in shares of Savara during the 3rd quarter valued at $3,780,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Savara during the 4th quarter valued at $74,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.